SCHEMBL1565038

SCHEMBL1565038

CCCCC(Oc1ccc(OC)c(OC)c1)C(=O)Nc1nccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ LMNA P02545 4/20 0.53
▸ KDM4E B2RXH2 1/20 0.50
▸ HSPA5 P11021 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ NPC1 O15118 4/20 0.47
▸ ADRB2 P07550 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ APEX1 P27695 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1565298 0.89 NPC1 (0.56) RAB9ASMN1; SMN2LMNAHSPA5L3MBTL1
SCHEMBL1565548 0.87 HSPA5 (0.49) RAB9ASMN1; SMN2LMNAHSPA5L3MBTL1
SCHEMBL1565655 0.87 HSPA5 (0.52) RAB9ASMN1; SMN2LMNAHSPA5L3MBTL1
SCHEMBL1565568 0.86 NPC1 (0.55) RAB9ASMN1; SMN2LMNAHSPA5L3MBTL1
SCHEMBL1565403 0.84 LMNA (0.50) RAB9ASMN1; SMN2LMNAKDM4EHSPA5
SCHEMBL1566200 0.84 NPC1 (0.58) RAB9ALMNAHSPA5L3MBTL1NPC1
SCHEMBL1565765 0.84 LMNA (0.53) RAB9ASMN1; SMN2MAPK1LMNAHSPA5
SCHEMBL1564907 0.84 TP53 (0.55) RAB9ASMN1; SMN2LMNAHSPA5L3MBTL1
SCHEMBL1565317 0.83 LMNA (0.56) RAB9ASMN1; SMN2LMNAKDM4EHSPA5
SCHEMBL2653915 0.83 SMN1; SMN2 (0.39) RAB9ASMN1; SMN2MAPK1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US claimed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP claimed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 — — EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 — — US disclosed
EP-1336607-A1 Amide derivatives as glucokinase activators NOVO NORDISK A/S (DK) 2003-08-20 — — EP disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK RAB9A 3291/4885SMN1; SMN2 3951/4885MAPK1 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback